期刊
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
卷 85, 期 4, 页码 847-853出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2021.05.050
关键词
AA; alopecia areata; baricitinib; clinician-reported; CTP-543; efficacy; hair loss; JAK; Janus kinase; patient-reported; randomized; ruxolitinib; safety; SALT; tofacitinib; trial
类别
资金
- Eli Lilly and Company
The study evaluated the efficacy and safety of baricitinib in patients with alopecia areata. The results showed that baricitinib was effective in patients with >= 50% scalp hair loss and well tolerated, supporting its use in this patient population.
Background: There are no treatments approved by the Food and Drug Administration for alopecia areata. Objective: To evaluate the efficacy and safety of baricitinib in patients with >= 50% scalp hair loss in a phase 2 study of adults with alopecia areata (BRAVE-AA1). Methods: Patients were randomized 1:1:1:1 to receive placebo or baricitinib 1 mg, 2 mg, or 4 mg once daily. Two consecutive interim analyses were performed after all patients completed weeks 12 and 36 or had discontinued treatment prior to these time points. The primary endpoint was the proportion of patients achieving a Severity of Alopecia Tool (SALT) score <= 20 at week 36. Logistic regression was used with nonresponder imputation for missing data. Results: A total of 110 patients were randomized (placebo, 28; baricitinib 1-mg, 28; 2-mg, 27; 4-mg, 27). The baricitinib 1-mg dose was dropped after the first interim analysis based on lower SALT30 response rate. At week 36, the proportion of patients achieving a SALT score of <= 20 was significantly greater in baricitinib 2-mg (33.3%, P = .016) and 4-mg (51.9%, P = .001) groups versus placebo (3.6%). Baricitinib was well tolerated with no new safety findings. Limitations: Small sample size limits generalizability of results. Conclusion: These results support the efficacy and safety of baricitinib in patients with >= 50% scalp hair loss.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据